Provider Differences in Biosimilar Uptake in the Filgrastim Market
The speed and extent of biosimilar penetration differ across provider types. Provider awareness and incentives are significantly associated with biosimilar uptake.
Evaluating HCV Screening, Linkage to Care, and Treatment Across Insurers
An optimized hepatitis C virus screening and linkage-to-care process reduces the number of patients lost to follow-up and improves linkage to care for Medicare, Medicaid, and commercially insured patients.
